US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CLIMB BIO INC

2.13

+0.12005.97%

Volume:327.89K

Turnover:694.25K

Market Cap:144.34M

PE:-3.07

High:2.18

Open:2.02

Low:2.02

Close:2.01

52wk High:8.60

52wk Low:1.05

Shares:67.76M

Float Shares:25.58M

Volume Ratio:1.32

T/O Rate:1.28%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.6934

EPS(LYR):-1.5343

ROE:-22.92%

ROA:-15.83%

PB:0.78

PE(LYR):-1.39

Loading ...

Overview Company News Filings

Climb Bio Inc. Announces Upcoming Webcast to Highlight CLYM116 and IgA Nephropathy Opportunities on September 29, 2025

Climb Bio Inc. to Participate in Cantor Global Healthcare Conference in New York

Climb Bio Initiated at Outperform by Baird

Climb Bio Inc. Reports Q2 2025 Financial Results; R&D Expenses Rise to $6.6M from $1.0M in 2024, Cash Position Strong at $187.4M

Climb Bio Q2 EPS $(0.13) Beats $(0.17) Estimate

Climb Bio Inc. Receives Regulatory Clearance for pMN Phase 2 Trial and Phase 1 Subcutaneous Budoprutug Trial, Enrollment Ongoing in ITP and SLE Clinical Trials

Climb Bio Inc: Cash Runway Expected Through 2027

THOMSON REUTERS

Press Release: Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

President and CEO Aoife Brennan Reports Disposal of Common Shares of Climb Bio Inc

Climb Bio Inc. Files Initial Beneficial Ownership Statement for Chief Business Officer Megan Wilson Perrin

Emily Pimblett, SVP Finance & CAO, Reports Disposal of Climb Bio Inc. Common Shares

Climb Bio Inc. Files Initial Statement of Beneficial Ownership for Cindy Driscoll, Senior Vice President, Finance

Press Release: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer

Climb Bio Initiated at Outperform by Oppenheimer

Oppenheimer Initiates Climb Bio at Outperform With $10 Price Target

MT Newswires Live

Climb Bio Inc. Conducted 2025 Annual Stockholders Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CLYM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CLYM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLYM\",,,,,undefined,":{"symbol":"CLYM","market":"US","secType":"STK","nameCN":"CLIMB BIO INC","latestPrice":2.13,"timestamp":1758130357914,"preClose":2.01,"halted":0,"volume":327893,"delay":0,"floatShares":25579273,"shares":67764100,"eps":-0.693447,"marketStatus":"Trading","change":0.12,"latestTime":"09-17 13:33:18 EDT","open":2.02,"high":2.18,"low":2.02,"amount":694254.6690744,"amplitude":0.079602,"askPrice":2.14,"askSize":242,"bidPrice":2.12,"bidSize":311,"shortable":3,"etf":0,"ttmEps":-0.693447,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1758139200000},"marketStatusCode":2,"adr":0,"listingDate":1628222400000,"exchange":"NASDAQ","adjPreClose":2.01,"preHourTrading":{"tag":"盘前","latestPrice":2.01,"preClose":2.01,"latestTime":"09:19 EDT","volume":1778,"amount":3564.325485,"timestamp":1758115179276},"postHourTrading":{"tag":"盘后","latestPrice":2.06,"preClose":2.01,"latestTime":"19:58 EDT","volume":2609,"amount":5349.97,"timestamp":1758067092817},"volumeRatio":1.321525},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLYM\",,,,,undefined,":{"symbol":"CLYM","floatShares":25579273,"roa":"-15.83%","roe":"-22.92%","lyrEps":-1.5343,"volumeRatio":1.321525,"shares":67764100,"dividePrice":0,"high":2.18,"amplitude":0.079602,"preClose":2.01,"low":2.02,"week52Low":1.05,"pbRate":"0.78","week52High":8.6,"institutionHeld":0,"latestPrice":2.13,"committee":0.124774,"eps":-0.693447,"divideRate":0,"volume":327893,"delay":0,"ttmEps":-0.693447,"open":2.02,"prevYearClose":1.8,"prevWeekClose":2.25,"prevMonthClose":2.23,"prevQuarterClose":1.24,"fiveDayClose":2.38,"twentyDayClose":2.02,"sixtyDayClose":1.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLYM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-12","symbol":"CLYM","fiscalQuarterEnding":"2025/06","expectedEps":-0.19,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.13},{"market":"US","date":"2021-09-13","symbol":"CLYM","fiscalQuarterEnding":"2021/06","expectedEps":-2.3,"name":null,"time":"","type":"earning","dateTimestamp":1631505600000,"reportTimeType":"","actualEps":-3.11}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLYM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLYM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":4,"updateTime":1755230400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CLYM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CLYM","date":"2025-09-16","current":-2.956473,"percent":0.26383,"low":-5.682799,"twenty":-3.160748,"median":-1.429631,"eighty":-1.050066,"high":-0.85032,"avg":-2.055014,"sd":1.274271,"marketCap":138238764},"quantilePoints":[{"date":"2024-10-04","current":-5.327624,"twenty":-5.327624,"median":-5.327624,"eighty":-5.327624,"marketCap":342006831},{"date":"2024-10-11","current":-5.369409,"twenty":-5.463426,"median":-5.390302,"eighty":-5.369409,"marketCap":344689237},{"date":"2024-10-18","current":-5.076912,"twenty":-5.494765,"median":-5.390302,"eighty":-5.327624,"marketCap":325912392},{"date":"2024-10-25","current":-4.85754,"twenty":-5.463426,"median":-5.327624,"eighty":-5.014234,"marketCap":311829757},{"date":"2024-10-31","current":-4.094958,"twenty":-5.404927,"median":-5.238831,"eighty":-4.776059,"marketCap":262875838},{"date":"2024-11-08","current":-3.677105,"twenty":-5.390302,"median":-5.014234,"eighty":-4.074065,"marketCap":236051773},{"date":"2024-11-15","current":-3.107258,"twenty":-5.373588,"median":-4.888879,"eighty":-3.806639,"marketCap":214779913},{"date":"2024-11-22","current":-2.917613,"twenty":-5.335981,"median":-4.293438,"eighty":-3.619939,"marketCap":201671280},{"date":"2024-11-29","current":-3.141297,"twenty":-5.327624,"median":-4.220314,"eighty":-3.127681,"marketCap":217132744},{"date":"2024-12-06","current":-2.830085,"twenty":-5.277482,"median":-3.974826,"eighty":-3.040153,"marketCap":195621141},{"date":"2024-12-13","current":-2.742557,"twenty":-5.237786,"median":-3.781569,"eighty":-2.995417,"marketCap":189571003},{"date":"2024-12-20","current":-1.896449,"twenty":-5.13959,"median":-3.671882,"eighty":-2.96235,"marketCap":131086332},{"date":"2024-12-27","current":-2.207661,"twenty":-5.051841,"median":-3.301766,"eighty":-2.921503,"marketCap":152597935},{"date":"2025-01-03","current":-2.013153,"twenty":-5.003788,"median":-3.151022,"eighty":-2.57139,"marketCap":139153183},{"date":"2025-01-10","current":-1.818646,"twenty":-4.962003,"median":-3.124277,"eighty":-2.236837,"marketCap":125708431},{"date":"2025-01-17","current":-1.954801,"twenty":-4.920218,"median":-3.063494,"eighty":-2.032604,"marketCap":135119757},{"date":"2025-01-24","current":-1.770019,"twenty":-4.870076,"median":-3.005142,"eighty":-1.952856,"marketCap":122347243},{"date":"2025-01-31","current":-1.876998,"twenty":-4.531614,"median":-2.995417,"eighty":-1.91979,"marketCap":129741856},{"date":"2025-02-07","current":-1.701941,"twenty":-4.324777,"median":-2.96624,"eighty":-1.892559,"marketCap":117641580},{"date":"2025-02-14","current":-1.546335,"twenty":-4.251653,"median":-2.932201,"eighty":-1.865328,"marketCap":106885778},{"date":"2025-02-21","current":-1.400454,"twenty":-4.228671,"median":-2.873849,"eighty":-1.840042,"marketCap":96802214},{"date":"2025-02-28","current":-1.351828,"twenty":-4.1451,"median":-2.528598,"eighty":-1.818646,"marketCap":93441026},{"date":"2025-03-07","current":-1.429631,"twenty":-4.03228,"median":-2.256288,"eighty":-1.756403,"marketCap":98818927},{"date":"2025-03-14","current":-1.293475,"twenty":-3.971692,"median":-2.18821,"eighty":-1.542445,"marketCap":89407600},{"date":"2025-03-21","current":-1.244848,"twenty":-3.871407,"median":-2.022879,"eighty":-1.474368,"marketCap":86046412},{"date":"2025-03-28","current":-1.159638,"twenty":-3.794104,"median":-1.954801,"eighty":-1.429631,"marketCap":85693751},{"date":"2025-04-04","current":-1.050066,"twenty":-3.724618,"median":-1.940213,"eighty":-1.381004,"marketCap":77596704},{"date":"2025-04-11","current":-1.059197,"twenty":-3.680923,"median":-1.925625,"eighty":-1.357663,"marketCap":78271458},{"date":"2025-04-17","current":-1.150507,"twenty":-3.672927,"median":-1.896449,"eighty":-1.324596,"marketCap":85018997},{"date":"2025-04-25","current":-1.187031,"twenty":-3.573219,"median":-1.876998,"eighty":-1.28764,"marketCap":87718013},{"date":"2025-05-02","current":-1.150507,"twenty":-3.328025,"median":-1.867273,"eighty":-1.252628,"marketCap":85018997},{"date":"2025-05-09","current":-1.088206,"twenty":-3.166583,"median":-1.847822,"eighty":-1.218825,"marketCap":80415162},{"date":"2025-05-16","current":-0.872124,"twenty":-3.152968,"median":-1.818646,"eighty":-1.187031,"marketCap":81090920},{"date":"2025-05-23","current":-0.872124,"twenty":-3.141297,"median":-1.818646,"eighty":-1.164325,"marketCap":81090920},{"date":"2025-05-30","current":-0.886659,"twenty":-3.134489,"median":-1.784607,"eighty":-1.159638,"marketCap":82442435},{"date":"2025-06-06","current":-0.901194,"twenty":-3.10434,"median":-1.750568,"eighty":-1.150507,"marketCap":83793951},{"date":"2025-06-13","current":-0.930265,"twenty":-3.086835,"median":-1.590099,"eighty":-1.125277,"marketCap":86496981},{"date":"2025-06-20","current":-0.893927,"twenty":-3.063494,"median":-1.522022,"eighty":-1.106495,"marketCap":83118193},{"date":"2025-06-27","current":-0.91573,"twenty":-3.014867,"median":-1.478258,"eighty":-1.095721,"marketCap":85145466},{"date":"2025-07-03","current":-0.930265,"twenty":-3.007087,"median":-1.439356,"eighty":-1.066502,"marketCap":86496981},{"date":"2025-07-11","current":-0.981139,"twenty":-2.997362,"median":-1.429631,"eighty":-1.007303,"marketCap":91227285},{"date":"2025-07-18","current":-1.061084,"twenty":-2.995417,"median":-1.400454,"eighty":-0.995674,"marketCap":98660619},{"date":"2025-07-25","current":-1.075619,"twenty":-2.995417,"median":-1.376141,"eighty":-1.007303,"marketCap":100012135},{"date":"2025-08-01","current":-1.017477,"twenty":-2.979856,"median":-1.361553,"eighty":-1.016024,"marketCap":94606073},{"date":"2025-08-08","current":-1.220973,"twenty":-2.968185,"median":-1.346965,"eighty":-1.017477,"marketCap":113527288},{"date":"2025-08-15","current":-2.492713,"twenty":-2.95846,"median":-1.351828,"eighty":-1.023291,"marketCap":116554252},{"date":"2025-08-22","current":-3.173861,"twenty":-2.979856,"median":-1.366416,"eighty":-1.024745,"marketCap":148403379},{"date":"2025-08-29","current":-3.333278,"twenty":-3.007087,"median":-1.381004,"eighty":-1.030392,"marketCap":155857430},{"date":"2025-09-05","current":-3.376756,"twenty":-3.075164,"median":-1.400454,"eighty":-1.031929,"marketCap":157890353},{"date":"2025-09-12","current":-3.478204,"twenty":-3.149077,"median":-1.429631,"eighty":-1.042845,"marketCap":162633840},{"date":"2025-09-16","current":-2.956473,"twenty":-3.160748,"median":-1.429631,"eighty":-1.050066,"marketCap":138238764}],"updateTime":1758099542920},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CLYM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2564376945","title":"Climb Bio Inc. Announces Upcoming Webcast to Highlight CLYM116 and IgA Nephropathy Opportunities on September 29, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2564376945","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564376945?lang=en_us&edition=fundamental","pubTime":"2025-09-04 19:01","pubTimestamp":1756983684,"startTime":"0","endTime":"0","summary":"Climb Bio Inc. has announced an upcoming webcast event to highlight its CLYM116 program, scheduled for September 29, 2025. The event will focus on CLYM116, a preclinical-stage monoclonal antibody targeting APRIL, a key factor in pathogenic B cell activity related to autoimmune diseases. Developed for the treatment of IgA nephropathy , CLYM116 employs a unique 'sweeper' mechanism of action intended to recycle the antibody and eliminate APRIL, potentially offering best-in-class efficacy with reduced dosing frequency. During the webcast, Climb Bio's management team and nephrologist Craig E. Gordon, MD, MS, will present an overview of IgAN, address unmet needs, and discuss the commercial opportunity for IgAN. Preclinical data comparing CLYM116 to a first-generation anti-APRIL monoclonal antibody, including head-to-head nonhuman primate results, will also be shared. Climb Bio plans to file an Investigational New Drug  application or Clinical Trial Application  for CLYM116 in the second half","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL1r2KkM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4539","BK4139","LU2095319765.USD","CLYM","IE00B64PRP62.GBP","LU2210150020.SGD","BK4588","LU0314104364.USD","NDAQ","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2562245582","title":"Climb Bio Inc. to Participate in Cantor Global Healthcare Conference in New York","url":"https://stock-news.laohu8.com/highlight/detail?id=2562245582","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562245582?lang=en_us&edition=fundamental","pubTime":"2025-08-25 19:00","pubTimestamp":1756119608,"startTime":"0","endTime":"0","summary":"Climb Bio Inc., a clinical-stage biotechnology company focused on developing therapeutics for immune-mediated diseases, is set to participate in the Cantor Global Healthcare Conference on September 5, 2025, in New York, NY. The company will engage in a fireside chat and hold one-on-one investor meetings during the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on August 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nNDL3Jhpzp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","CLYM","LU0314104364.USD","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","IE00B3QW5Z07.USD","BK4539","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210150020.SGD","BK4139","BK4112","LU2210149790.SGD"],"gpt_icon":0},{"id":"2559641917","title":"Climb Bio Initiated at Outperform by Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2559641917","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559641917?lang=en_us&edition=fundamental","pubTime":"2025-08-15 22:29","pubTimestamp":1755268140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 15, 2025 10:29 ET (14:29 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM"],"gpt_icon":0},{"id":"2558494036","title":"Climb Bio Inc. Reports Q2 2025 Financial Results; R&D Expenses Rise to $6.6M from $1.0M in 2024, Cash Position Strong at $187.4M","url":"https://stock-news.laohu8.com/highlight/detail?id=2558494036","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558494036?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:11","pubTimestamp":1754997079,"startTime":"0","endTime":"0","summary":"Climb Bio Inc. Reports Q2 2025 Financial Results; R&D Expenses Rise to $6.6M from $1.0M in 2024, Cash Position Strong at $187.4M. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL3BGzGL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CLYM","BK4139"],"gpt_icon":0},{"id":"2558649234","title":"Climb Bio Q2 EPS $(0.13) Beats $(0.17) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2558649234","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558649234?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:10","pubTimestamp":1754997044,"startTime":"0","endTime":"0","summary":"Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 92.82 percent increase over losses of $(1.81) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47054600/climb-bio-q2-eps-0-13-beats-0-17-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM"],"gpt_icon":0},{"id":"2558649175","title":"Climb Bio Inc. Receives Regulatory Clearance for pMN Phase 2 Trial and Phase 1 Subcutaneous Budoprutug Trial, Enrollment Ongoing in ITP and SLE Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2558649175","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558649175?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:01","pubTimestamp":1754996493,"startTime":"0","endTime":"0","summary":"Climb Bio Inc. Receives Regulatory Clearance for pMN Phase 2 Trial and Phase 1 Subcutaneous Budoprutug Trial, Enrollment Ongoing in ITP and SLE Clinical Trials. Climb Bio Inc., a clinical-stage biotechnology company, has announced significant regulatory milestones in their ongoing efforts to advance treatments for immune-mediated diseases. The company has achieved regulatory clearance to initiate the Phase 2 trial of budoprutug for Primary Membranous Nephropathy  and the Phase 1 trial of subcutaneous budoprutug in healthy volunteers. These trials are expected to commence shortly, marking a step forward in Climb Bio's pipeline development. Additionally, Climb Bio is preparing for an IND or CTA submission for IgA Nephropathy  in the second half of 2025. These advancements underscore Climb Bio's commitment to bringing innovative treatments to patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide acc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL5z29dN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4539","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","LU0314104364.USD","CLYM","LU2210149790.SGD","BK4588","IE00B64PRP62.GBP","BK4112","LU2210150020.SGD","BK4139","IE00BKPKM429.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2558649928","title":"Climb Bio Inc: Cash Runway Expected Through 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2558649928","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558649928?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:00","pubTimestamp":1754996402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nTUA5BKBRJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","CLYM"],"gpt_icon":0},{"id":"2558498626","title":"Press Release: Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2558498626","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558498626?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:00","pubTimestamp":1754996400,"startTime":"0","endTime":"0","summary":"Trial of Budoprutug in Primary Membranous Nephropathy  Expected to Initiate in the Coming Weeks. Budoprutug Subcutaneous Formulation Demonstrated High Bioavailability and Favorable Tolerability in Non-clinical Studies;Phase 1 Trial Expected to Initiate in the Coming Weeks, with Initial Data Anticipated in First Half 2026. CLYM116 Focused Webcast Event, Including New Preclinical Data, Planned for September 2025;IND or CTA Submission for IgA Nephropathy  Expected in Second Half 2025. Strong Financial Position, with Cash Runway Expected Through 2027. WELLESLEY HILLS, Mass., Aug. 12, 2025  -- Climb Bio, Inc. , a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2025 and provided business updates.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","CLYM","BK4199","BMS","SLE","BK4539","CTA","BK4077","BK4139"],"gpt_icon":0},{"id":"2548188769","title":"President and CEO Aoife Brennan Reports Disposal of Common Shares of Climb Bio Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2548188769","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548188769?lang=en_us&edition=fundamental","pubTime":"2025-07-02 04:37","pubTimestamp":1751402272,"startTime":"0","endTime":"0","summary":"Aoife Brennan, President and CEO of Climb Bio Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nNDL435ZVk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CLYM"],"gpt_icon":0},{"id":"2545447158","title":"Climb Bio Inc. Files Initial Beneficial Ownership Statement for Chief Business Officer Megan Wilson Perrin","url":"https://stock-news.laohu8.com/highlight/detail?id=2545447158","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545447158?lang=en_us&edition=fundamental","pubTime":"2025-06-24 04:16","pubTimestamp":1750709767,"startTime":"0","endTime":"0","summary":"Climb Bio Inc. has filed an initial statement of beneficial ownership. The filing identifies Megan Wilson Perrin as the beneficial owner, who holds the position of Chief Business Officer at the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL4L5Htk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CLYM"],"gpt_icon":0},{"id":"2545170736","title":"Emily Pimblett, SVP Finance & CAO, Reports Disposal of Climb Bio Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2545170736","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545170736?lang=en_us&edition=fundamental","pubTime":"2025-06-21 04:20","pubTimestamp":1750450835,"startTime":"0","endTime":"0","summary":"Emily Pimblett, SVP, Finance & CAO of Climb Bio Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 20, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDLb7FblX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Emily Pimblett, SVP Finance & CAO, Reports Disposal of Climb Bio Inc. Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4539","BK4139"],"gpt_icon":0},{"id":"2545299170","title":"Climb Bio Inc. Files Initial Statement of Beneficial Ownership for Cindy Driscoll, Senior Vice President, Finance","url":"https://stock-news.laohu8.com/highlight/detail?id=2545299170","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545299170?lang=en_us&edition=fundamental","pubTime":"2025-06-21 04:15","pubTimestamp":1750450556,"startTime":"0","endTime":"0","summary":"Climb Bio Inc. has filed an initial statement of beneficial ownership with the United States Securities and Exchange Commission. The filing identifies Cindy Driscoll as the beneficial owner, serving in the role of Senior Vice President, Finance. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 20, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL1GxTtm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM","BK4539"],"gpt_icon":0},{"id":"2544149979","title":"Press Release: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2544149979","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544149979?lang=en_us&edition=fundamental","pubTime":"2025-06-18 19:00","pubTimestamp":1750244400,"startTime":"0","endTime":"0","summary":"Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise. Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance. WELLESLEY HILLS, Mass., June 18, 2025  -- Climb Bio, Inc. , a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced the appointments of Edgar D. Charles, M.D., MSc as its Chief Medical Officer  and Cindy J. Driscoll, MBA as Senior Vice President, Finance.Dr. Charles holds a Doctor of Medicine from the University of Alabama School of Medicine, a Master of Science in Clinical and Translational Investigation from Rockefeller University, and a Bachelor of Arts in Economics from the University of Chicago. He completed his Internal Medicine residency and Infectious Diseases fellowship at N","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4539","BK4139","BMS"],"gpt_icon":0},{"id":"2541862681","title":"Climb Bio Initiated at Outperform by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2541862681","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541862681?lang=en_us&edition=fundamental","pubTime":"2025-06-07 01:21","pubTimestamp":1749230460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 06, 2025 13:21 ET (17:21 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","OPY"],"gpt_icon":0},{"id":"2541854877","title":"Oppenheimer Initiates Climb Bio at Outperform With $10 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2541854877","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541854877?lang=en_us&edition=fundamental","pubTime":"2025-06-06 19:13","pubTimestamp":1749208418,"startTime":"0","endTime":"0","summary":"Oppenheimer Initiates Climb Bio at Outperform With $10 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPY","CLYM"],"gpt_icon":0},{"id":"2541005802","title":"Climb Bio Inc. Conducted 2025 Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2541005802","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541005802?lang=en_us&edition=fundamental","pubTime":"2025-06-06 04:06","pubTimestamp":1749153968,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL5BqBdM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4539","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}]}}